Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Cryoablation and Nephrectomy in RCC
NCT03189186Phase 1Withdrawn
- Sponsor
- University of California, Irvine
- Start
- Jul 2017
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in renal cell carcinoma (RCC), sponsored by University of California, Irvine. Primary endpoint: Overall Response Rate at 24 weeks. Planned start Jul 2017; status: withdrawn.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03189186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189186.